Sign in
CompletedPhase 2

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Key facts

Who runs it
MediciNova
Where
Denver and New Haven, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
34 people enrolled
Started
11 Jan 2021
Ended
7 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ibudilast
  • Placebo
Record updated
30 October 2024

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • SARS-CoV-2 infection confirmed with WHO criteria (including a positive PCR of any specimen, e.g., blood, respiratory, stool, urine, or any other body fluid)
  • Chest imaging (radiograph, computerized tomography (CT) scan or lung ultrasound) with abnormalities consistent with COVID-19 pneumonia
  • Oxygen saturation (SpO2) ≤92% on room air (RA), respiratory rate ≥24 breaths per min on RA, and/or requirement for supplemental oxygen
  • At least 1 risk factor which may put patient at higher risk for more severe illness from COVID-19: Age > 65, underlying serious heart disease, chronic lung disease, moderate to severe asthma, body mass index of ≥40, or diabetes

Who cannot take part

  • Known or suspected immunosuppression with immunosuppressant medications or chemotherapeutic agents
  • Patient is receiving dialysis treatment
  • Suspected active bacterial, fungal, viral, or other cause of respiratory failure other than COVID-19
  • On a home ventilator support or continuous domiciliary oxygen therapy for baseline lung disease
  • Active tuberculosis infection
  • Subject is already intubated and on ventilator support

Where in United States

  • Denver Health and Hospital AuthorityDenver, United States
  • Yale University School Of MedicineNew Haven, United States

About the trial

What the trial wants to find out

The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care (including anticoagulation therapy) by measuring the following outcomes: 1) the need for oxygen therapy at Days 7, 14, and 28, 2) clinical status as measured by the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale at Days 7, 14, and 28, and 3) safety (as measured by incidence of adverse events and clinical laboratory findings) and tolerability of Ibudilast.

The 2 groups in the trial

  • Active Treatment GroupTreatment being tested

    Treatment: Ibudilast

  • Placebo Treatment GroupPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome
Publications
Record updated
30 October 2024